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Background: 123I-CMICE-013 is a novel radiotracer previously reported to have promising characteristics for
single-photon emission computed tomography (SPECT) myocardial perfusion imaging. We evaluated the biokinetics
and radiodosimetry of this rotenone-like 123I-labeled tracer in a microSPECT imaging-based study.
Methods: 37 to 111 MBq of 123I-CMICE-013 was synthesized and administered intravenously to 14 healthy rats.
Images were acquired with a microSPECT/CT camera at various time intervals and reconstructed to allow activity
quantification in the tissues of interest. Radiation dosage resulted from the injection of 123I-CMICE-013 was estimated
base on the biodistribution data. Tissue uptake values from image analysis were verified by gamma-counting dissected
organs ex vivo.
Results: The heart/stomach and heart/intestine uptake ratios peaked shortly after the injection of 123I-CMICE-013,
meanwhile the heart/liver ratio reached 2 as early as at 23 min post-injection. Little activity was observed in the lung
and overnight clearance was significant in most of the measured tissues. The radiation dosimetry analysis based
on the time-activity curves provided an estimate of the effective human dose of 6.99E-03 mSv/MBq using ICRP
60 and 7.15E-03 mSv/MBq using ICRP 103, which is comparable to the popular myocardium perfusion imaging
(MPI) agents such as 99mTc-tetrofosmin and 99mTc-sestamibi, as well as other 123I-based radiotracers.
Conclusions: 123I-CMICE-013 demonstrated desirable characteristics in its biokinetic and radiodosimetric profiles,
supporting its potential application as a novel myocardial perfusion imaging agent.
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The assessment of myocardial perfusion is an important
component of the evaluation of patients with coronary
artery disease (CAD). Compared to other non-invasive
imaging modalities such as positron emission tomography,
and cardiac magnetic resonance imaging, single-photon
emission computed tomography (SPECT) remains the
most commonly used modality for myocardial perfusion
imaging (MPI) due to its cost effectiveness, wide availabil-
ity of SPECT cameras and its well validated methodology.* Correspondence: daniel.duan@nordion.com
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in any medium, provided the original work is pMPI using 201Tl or 99mTc-based agents (e.g. 99mTc-sesta-
mibi and 99mTc-tetrofosmin) has been the dominant
SPECT diagnostic method for identifying and characteriz-
ing CAD. However, the relatively low first-pass myocardial
extraction of these 99mTc tracers at high flow rates limits
the contrast obtained between normal and abnormal
tissues [1,2]. And their proximal gastrointestinal activity
uptake can sometimes create unwanted scattering to
the myocardium [1-4]. Usually considered as an alter-
native, 201Tl also has quite a few undesirable characteristics:
the low energy of the primary emission peak at 80 keV
results in increased attenuation of the signal [2], the
long physical half-life of 73 h limits the injected dose and
leads to both noisier images and a high radiation exposure
(2.2E-01 mSv/MBq according to ICRP 80 [5]), and itsOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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following injection for accurate stress images [1,2].
Our group previously reported the radiolabeling and
purification of an iodinated rotenone molecule 123I-
CMICE-013, a radioiodinated derivative of rotenone [6].
This new radiotracer is a potential alternative to the
conventionally used MPI tracers such as 201Tl, 99mTc-
sestamibi or 99mTc-tetrofosmin. Preliminary experiments
in healthy rats have demonstrated the clear visualization
of the myocardium and limited background activity using
microSPECT/CT imaging. Imaging with 123I-CMICE-013
of chronic occlusion and ischemia/reperfusion rat models
demonstrated excellent images of myocardial defects,
which correlated well with ex vivo staining with triphe-
nyltetrazolium chloride (TTC) [6].
In the current study, we acquired microSPECT/CT
images at various time points to better understand the
in vivo kinetic profile of 123I-CMICE-013 in healthy rats
and quantified the activity in various organs. Time-
activity curves were constructed to evaluate the uptake of
tracers in the myocardium and other organs. We compared
the data from imaging-based analysis to those acquired
through tissue dissection and gamma counter measure-
ment, and verified the accuracy of the image-based quanti-
fication approach. Radiation dosimetry is an important
metric for evaluating the safety of a novel radioactive
imaging agent. The internal radiation exposure of 123I-
CMICE-013 was assessed using the resident activities
data from the imaging biodistribution.
Methods
Materials
Analytical grade chemicals and solvents were used in
this study without further purification. Rotenone was
purchased from Sigma Aldrich (St. Louis, MO, USA).
Iodine-123 isotope was provided by Nordion Inc
(Ottawa, ON, Canada). A preparative high-performance
liquid chromatography (HPLC) system was assembled
using Dionex GP50 gradient pump (Sunnyvale, CA, USA),
Waters Fraction Collector III (Milford, MA, USA), and
Rheodyne 7725i six-port sample injection valve. Analytical
HPLC was performed on a Waters system (Milford, MA,
USA) with a 1525 Pump, 2998 Photodiode Array Detector,
and 717+ Autosampler. A PerkinElmer 150TR Flow Scin-
tillation Analyzer (Waltham, MA, USA) was connected to
the analytical HPLC system and utilized as a radio-signal
detecting module. A Capintec CRC-25R Dose calibrator
(Ramsey, NJ, USA) was used to measure the radioactivity
of 123I-CMICE-013 injections.
Radiosynthesis of 123I-CMICE-013
The radiosynthesis of 123I-CMICE-013 follows the method
described in our previous publication [6]. Briefly, 463 MBq
(12.5 mCi) of Iodine-123 (in the form of Na123I in 0.1 MNaOH) was added into a 1.5-mL microtest tube. Then,
170 μL of rotenone (2.5 mg/mL, dissolved in trifluoroacetic
acid) and 30 μL iodogen (0.75 mg/mL, dissolved in trifluor-
oacetic acid) were added sequentially, with the resulted
molar ratio of rotenone versus iodogen at 21:1. The reac-
tion was carried out at 60°C with mixing at 600 rpm for
45 min. After brief cooling, reaction mixture was injected
into the preparative HPLC system consisting of Luna C18
(2) reversed phase column (Phenomenex, Torrance, CA,
USA). Mobile phase ethanol/water (50%/50%, v/v) was
pumped into the system at the flow rate of 0.7 mL/min and
fraction collecting (0.7 mL/fraction) began right after the
injection. The identity/radiochemical purity (RCP) of the
collected product was first examined on analytical HPLC
and then underwent re-formulation. The final product
of 123I-CMICE-013 was re-constituted in a 5% EtOH
(v/v) 10 mM NaOAc at pH 6.5. The radiochemical purity
of the final product was ≥95%, pH was between 3 and 7,
and the alcohol percentage was between 3% and 7%.
123I-CMICE-013 microSPECT/CT imaging
All animal experiments were conducted in compliance
with the guidelines of the Canadian Council on Animal
Care (CCAC) and with approval from the Animal Care
Committee (ACC) at the University of Ottawa. For the
study, a total of 14 Sprague–Dawley rats (Charles River
Laboratories, Wilmington, MA, USA) weighing 251 ± 16 g
were divided into two groups. Animals in group A (n = 6)
were repeatedly scanned for 15-min acquisitions at 20-min
intervals from immediately to 2 h after injection of 123I-
CMICE-013. Rats in group B (n = 8) were first injected
with the tracer, then allowed to recover from anesthesia
before returning to regular housing, and imaged using two
1-h acquisitions at 24 h post-injection. The amount of
injected tracer activity was between 37 and 111 MBq (1 to
3 mCi). All rats were sedated under light anesthesia with
1% to 2% isoflurane delivered through a nose cone during
tracer injection as well as imaging.
A NanoSPECT/CT scanner (Bioscan, Washington, DC,
USA) was used in the study. The scanner has 4 NaI de-
tectors, each with a 9 × 2.5-mm-diameter multi-pinhole
collimator. During imaging, the rats were placed in the
supine position and their temperature maintained
throughout the imaging session with a Minerva heated
scanner bed (Bioscan, Washington, DC, USA). Projection
data were acquired with a spiral scan covering the full
body of the rat. A single 10-min whole-body CT scan was
acquired prior to the SPECT acquisition for localization
of tracer uptake. A calibrated source of 123I was placed
within the SPECT field of view in order to facilitate
image quantification. The animals' respiration and heart
rate were monitored during the scanning process with a
Model 1025 T Small Animal Monitoring System (BioScan,
Washington DC, USA).
Table 1 Organ masses of both rat and human used in the
radiodosimetry analysis [7]






Bladder (contents) 0.89 102
Intestine (ULI) 5.54 220
Intestine (LLI) 3.4 135
Intestine (small) 5 400
Remainder 224 66,573
Total body 251 70,000
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Images were reconstructed using HiSPECT software pro-
vided by the camera manufacturer (BioScan, Washington,
DC, USA). The reconstruction algorithm was ordered
subset expectation maximization (OSEM) using a pro-
gressively small number of subsets: eight iterations
of six subsets (8 × 6), followed by 8 × 4 and 8 × 1. The
reconstructed voxel size was 0.6 × 0.6 × 0.6 mm. The
reconstruction included collimator modeling but no
correction for attenuation or scatter. Images were
post-reconstruction filtered using a 3D Gaussian filter
with a full width at half maximum of 0.63 mm. Images
acquired at 3, 23, 43, 62, 82, and 102 min and 24 h
after the radiotracer injection were analyzed with
MATLAB (MathWorks, Boston, MA, USA). For each
rat, the set of acquired images were summed together.
Manual volumes of interest (VOI) were drawn around
all areas of focal uptake in the summed image. The
VOI was restricted to the region above soft-tissue
background and applied separately to the images from
each time point. The total counts in each VOI at each
time point were decay-corrected and recorded. A VOI
was designated around the 123I calibration source and
the average decay-corrected counts in the source were
used to convert the measured counts to activity. The
activity in each VOI was associated with organs with
the assistance of the CT scan. The percentage injected
dose per organ (%ID/organ) at a certain time point were
calculated by dividing the activity at the VOI region by the
injection dose value as measured on the dose calibrator.
Tissue biodistribution
Following image acquisition, animals were euthanized:
group A at 2 h and group B at 24 h after tracer injection.
Their heart, liver, kidney, muscle, femur, spleen, blood,
brain, intestine, lung, stomach, urine/bladder, ovaries/
testes, and thyroid were extracted, weighed, and analyzed
for total gamma counts using a PerkinElmer Wizard3
2480 Automatic Gamma Counter (Waltham, MA, USA).
The tissue uptake is represented as the %ID/organ.
Dosimetry estimation
From the imaging biodistribution study, the %ID/organ
values as a function of time were averaged over rats and
integrated to calculate the residence times of the tracer in
each organ. The rat residence times were converted into hu-
man residence times by multiplying the rat residence time



















where mTB is the total body mass of the rat or human, and
morgan is the mass of tissue or organ of the rat or human(see Table 1), and %IDorgan is the percentage of injected dose
for the organ in question for the rat or human [7].
The resultant human residence times were then entered
into OLINDA/EXM [8], which employs the MIRD method
in conjunction with the ICRP publication protocols [8-10].
Specifically, the effective dose (ED) was calculated accord-
ing to ICRP 60 [9] without the splitting rule, and ICRP 103
[11]. However, there are no published tissue dose factors
available for the esophagus, salivary glands, extrathoracic
region, lymphatic nodes, oral mucosa, or prostate, which
are required for the complete calculation using ICRP 103.
Therefore adjustments to the final dose had to be made
through increasing the effective dose in proportion to the
total tissue weighting factor in order to compensate
for the unaccountable organs. Such adjustment, though
not ideal, is deemed acceptable according to the code
developer of OLINDA/EXM. The percentage increase of
effective dose was calculated using the weighting factors
in ICRP 103 (see Table 2). The weighting factors for
the tissues without dose factors are: esophagus, 0.04;
salivary glands, 0.01; additionally, the extrathoracic region,
lymphatic nodes, oral mucosa and prostate as a part of
remainder, 0.12*(4/13) male and 0.12*(3/13) female.
This accounts for a cumulative tissue weighting factor
of 0.0869 (or 8.69%) for male, and 0.0777 (or 7.77%) for
female, shown by the calculations below.
Male : 0:04þ 4
13
0:12þ 0:01 ¼ 0:0869
Female : 0:04þ 3
13
0:12þ 0:01 ¼ 0:0777
Data analysis and statistics
Average values (mean) and corresponding standard
deviation (SD) were calculated with Microsoft Excel
(Redmond, WA, USA) and expressed as mean ± SD,
Table 2 Tissue weighting factors in ICRP 103 [11]
Tissue/Organ Weighting factor




Bladder, liver, esophagus, thyroid 0.04
Bone surfaces, brain, salivary glands, skin 0.01
The following 13 tissues/organs were considered as parts of the ‘Remainder’ in
the dosimetry estimate: adrenal glands, extrathoracic region, gall bladder,
heart, kidneys, lymphatic nodes, muscle, oral mucosa, pancreas, small
intestine, spleen, thymus, and prostate (male), or uterus/cervix (female).
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rest of the analysis was performed options using Prism 5
(GraphPad, La Jolla, CA, USA) software. In order to deter-
mine the difference among various groups of data, we ap-
plied Kruskal-Wallis non-parametric one-way analysis ofFigure 1 MicroSPECT images. A panel of coronal whole-body images of a
of 45 MBq 123I-CMICE-013 (A). The circled areas are indicated as the heart, live
identified as the thyroid, stomach, 123I source, and bladder. Volumes of interes
of focal uptake in the 23- to 102-min summed images (B).variance with matched measurement, followed by Dun-
nett's post-hoc test. When comparing data from this study
and literature, a simple one-way analysis of variance was
applied, followed by Dunnett's post-hoc test. For compar-
ing imaging and tissue biodistribution measurements, a
two-tailed paired Student's t test was used. A correlation
analysis was also performed on data acquired through the
two methods and a Pearson correlation coefficient (r) was
calculated. A P value of <0.05 was considered to be statis-
tically significant.Results
123I-CMICE-013 imaging biodistribution
The time course of the distribution of 123I-CMICE-013 is
shown in the microSPECT images in Figure 1A. Figure 1B
illustrates VOIs drawn around the organ of interest for the
purpose of quantification of the absorbed activity. Veryhealthy rat at 3, 23, 43, 62, 82, and 102 min and 24 h after the injection
r, large intestine, and stomach. The bright spots in the 24-h image were
t (VOIs) for imaging biodistribution analysis were drawn around all areas
Figure 2 Representative time-activity density curves. The
percentage of injected dose by organ volume (%ID/cm3) from heart,
liver, intestine, and stomach, expressed as mean ± SD (n = 6), were
plotted against time (3 to 102 min) to demonstrate the activity density.
* P < 0.05, ** P < 0.001, *** P < 0.0001 versus the data points at 3 min.
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accumulate in the myocardium, with excellent contrast to
the surrounding tissues such as lung and liver. Later on at
43 to 62 min, the radioactivity increases in the stomach
and intestine. At 24 h post-injection, most of the activity
has been cleared from the heart, intestine and liver.
The calculated percentage-injected dose values are
presented in Table 3. Due to the lack of activity in the
lung during the scan, no VOI was drawn at the lung
and no %ID/organ value is presented for lung in this
table. To better understand the organ activity density,
%ID/organ values were divided by the volume of the
organ. The volume of organ was estimated as the num-
ber of voxels in the VOI surrounding the organ that
contained activity greater than the background. Each
voxel had a size of 0.6 × 0.6 × 0.6 mm which is equiva-
lent to 2.16E-04 mL or cm3. The resultant %ID/cm3
plotted against time is presented in Figure 2. The activ-
ity density of the myocardium showed a gradual decline
that did not become significantly different (P < 0.05)
until 1 h after the administration of the tracer. The
measurements in the intestine and stomach showed an
increase over the time and reached 9.423 ± 4.275 %ID/cm3
and 10.098 ± 5.763 %ID/cm3, respectively, at the end of
the scan.
Uptake ratios were calculated by dividing the activity
density of the heart by the other three organs and shown
in Figure 3. The heart/liver ratio (Figure 3A) remained
between 2 and 2.5 for almost the entire scan and reach
a maximum (2.382 ± 0.588) at the last time interval.
The heart/stomach ratio (Figure 3B) and heart/intestine
(Figure 3C) however demonstrated a decreasing trend -
from almost 1 at the beginning to 0.2 at the end (0.223 ±
0.081 and 0.225 ± 0.112, respectively) - indicating the tracer
accumulated in both organs. The heart/liver ratio of 123I-
CMICE-013 (2.365 ± 0.554; Figure 4) appears to be higher
or similar to two other rotenone-derived radiotracers
7′(Z)-125I-iodorotenol (1.136 ± 0.048) and 7′(Z)-125I-
iodorotenone (2.402 ± 0.209) from a previous report [12].Table 3 Biodistribution of 123I-CMICE-013 in healthy Sprague–
Organ %ID/
2 min 23 min 43 min
Thyroid 0.47 ± 0.20 0.48 ± 0.19 0.48 ± 0.17
Stomach 6.70 ± 2.25 7.84 ± 1.68 8.71 ± 1.24
Liver 17.96 ± 4.46 13.84 ± 4.63 11.39 ± 4.21
Heart 4.18 ± 0.99 3.69 ± 0.77 3.24 ± 0.70
Bladder 0.15 ± 0.19 0.42 ± 0.40 0.52 ± 0.49
Intestine 4.69 ± 2.78 5.81 ± 2.91 7.63 ± 3.24
Sal. gland 2.97 ± 1.12 3.04 ± 1.16 3.06 ± 1.16
Fourteen animals were divided into two groups. Group no. 1 (n = 6) was used in 0-
post-injection, no activity was observed in the microSPECT images of the liver, hearIt is also close to 99mTc-sestamibi (2.6 ± 0.2) but only around
one half of 99mTc-tetrofosmin (5.8 ± 0.7) [13].
A graph of %ID/organ values at 102 min and 24 h
showed an overnight clearance of most activity on a whole-
body scale (Figure 5). Only four organs (thyroid, stomach,
bladder, and intestine) were observed to have activity above
background, and among them, both the stomach and
intestine showed a significant drop of activity (P < 0.0001).
The remainder %ID/organ also decreased significantly
(P < 0.0001) between 102 min and 24 h, indicating a
massive excretion of background activity.
Imaging biodistribution versus tissue biodistribution
In order to verify the accuracy of the imaging biodistri-
bution approach, the %ID/organ values calculated from
microSPECT images at 2 h post-injection were compared
to the %ID/organ values generated from tissue extraction
and gamma well counting (Figure 6). Only data from
six organs were compared because the salivary glandDawley rats
organ (mean ± SD)
62 min 82 min 102 min 24 h
0.48 ± 0.17 0.49 ± 0.15 0.49 ± 0.14 0.69 ± 0.23
10.10 ± 0.98 11.60 ± 1.10 13.09 ± 1.58 1.30 ± 0.34
9.61 ± 3.59 8.30 ± 3.19 7.39 ± 2.95 n/a
2.81 ± 0.62 2.43 ± 0.56 2.16 ± 0.48 n/a
0.56 ± 0.52 0.61 ± 0.56 0.64 ± 0.57 0.16 ± 0.07
8.28 ± 3.18 8.06 ± 3.07 7.91 ± 3.02 0.58 ± 0.33
3.05 ± 1.16 3.00 ± 1.13 2.95 ± 1.11 n/a
to 2-h imaging and group no. 2 (n = 8) was used in 24-h imaging. At 24 h
t, and salivary gland.
Figure 3 Heart/organ uptake ratios. The %ID/cm3 of heart was
divided by that of liver, stomach, and intestine to calculate the uptake
ratio of heart/liver (A), heart/stomach (B) and heart/intestine ratios
(C) at different time points post-injection of the tracer. Data were
presented as mean ± SD (n= 6). * P < 0.05, ** P < 0.001, *** P < 0.0001
versus the data points at 3 min.
Figure 4 Heart/liver ratio of 123I-CMICE-013 versus other
perfusion agents. The heart/liver ratio of 123I-CMICE-013 at 62 min
(approximately 1 h) was compared to that of 7′(Z)-125I-iodorotenol,
7'(Z)-125I-iodorotenone, 99mTc-tetrofosmin, and 99mTc-sestamibi [12,13].
The ratio of 123I-CMICE-013 was expressed as mean ± SD (n = 6);
7'(Z)-125I-iodorotenol, 7'(Z)-125I-iodorotenone as mean ± SD (n = 3,
7); and 99mTc-tetrofosmin, 99mTc-sestamibi as mean ± SEM (n = 5,
5). ** P < 0.001, *** P < 0.0001 versus 123I-CMICE-013.
Figure 5 Tissue uptake of 123I-CMICE-013 at 102 min versus
24 h post-injection. Due to no evident activity in the microSPECT
image at 24 h, no %ID/organ values were registered in VOI for the
liver, heart, or salivary gland. The %ID/organ values were expressed as
mean ± SD. n = 6 for 102-min data, n = 8 for 24-h data. *** P < 0.0001
versus values at 102 min.
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no significant difference between the two groups of
data for any of the considered organs (P > 0.05) except
for the intestine (P = 0.03).
In order to further evaluate the correlation of the data
acquired with the two different methods, a Pearson correl-
ation coefficient (r) was calculated based on the scatter
plots of imaging and tissue biodistribution data. Figure 7
demonstrated a strong correlation overall (r = 0.882,
P < 0.0001). A linear fit to the data has a slope of 1.144
and an intercept of 0.669 %ID/organ.Vital sign monitoring
No significant change in respiratory rate or heart rate
was observed over the time from 0 to 2 h during the
scan. The mean values were 55 ± 13 and 373 ± 34 for the
respiratory rate and heart rate, respectively.
Radiodosimetry analysis
The averaged %ID/organ values from 3 to 102 min are
shown in Figure 8. The residence times (Bq-h/Bq) of organs
and remainder are given in Table 4. The heart and liver
show clear signs of continuous clearance; therefore, an
Figure 6 Comparison of imaging and tissue biodistribution in six organs. The %ID/organ values were expressed as mean ± SD (n = 6).
No significant difference was observed except in the intestine.
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two organs and integrated to calculate the residence times.
With respect to other organs, given the long physical half
life of 123I (t1/2 = 13.2 h), we used the assumption that the
remaining activity in the body at 102 min (1.7 h) would
decay to zero without any excretion, in order to provide a
conservative estimate of the residence times.
Rat residence times were converted to human residence
times and OLINDA/EXM was used to calculate the dose
to target organs. The value of intestine was split up among
the upper large intestine (ULI), lower large intestine (LLI),
and the small intestine (SI), by proportion to the mass of
these three organs. The salivary glands were added to the
remainder in this analysis.
Table 5 listed analysis results for the whole-body effect-
ive dose (6.99E-03 mSv/MBq for ICRP 60; 7.15E-03 mSv/
MBq for ICRP 103) as well as the doses to various targetorgans. The stomach was seen to accumulate the highest
dose 1.36E-02 mSv/MBq for male and 1.64E-02 mSv/MBq
for female, seconded by the thyroid 1.24E-02 mSv/MBq
for male and 1.44E-02 mSv/MBq for female. The dose of
the intestine was represented by ULI 6.92E-03 mSv/MBq
for male and 8.44E-03 mSv/MBq for female, LLI 6.63E-
03 mSv/MBq for male and 7.96E-03 mSv/MBq for female,
and SI 6.82E-03 mSv/MBq for male and 7.80E-03 mSv/
MBq for female. Considering the two major metabolism
organs, the dose of kidney was 4.87E-03 mSv/MBq for
male and 6.08E-03 mSv/MBq for female, whereas liver
was 5.76E-03 mSv/MBq for male and 7.48E-03 mSv/MBq
for female. Based on this estimate and the available data
from ICRP 80 [5] (Table 6), 123I-CMICE-013 has a modest
radiodosimetric profile.
It should be noted that our assessment of human equiva-
lent effective dose is based on the converted residence
Figure 7 Correlation between imaging and tissue biodistribution.
Each of the total 36 spots in the graph represents a pair of %ID/organ
values per tissue of one of the six animals.
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netics will be similar between small rodents and humans.
Although this approach can be utilized to evaluate the dos-
imetry of novel radiotracers in preclinical studies [14,15],
the biokinetics of tracers are often different between
rodents and humans. Thus, the dosimetry derived from
rat studies is, at best, a rough estimate. Future dosimetry
investigations in other species including humans are
required to confirm the safety of 123I-CMICE-013.
Discussion
123I-CMICE-013 represents a novel radioiodine-labeled
rotenone-derived MPI agent and is currently under the
investigation in our laboratory. In this study, by perform-
ing quantitative microSPECT image analysis, we showed
high heart uptake of 123I-CMICE-013 and a favorable
biodistribution profile. Images showed a rapid myocardial
uptake soon after administration, with little or no interfer-
ence from surrounding tissues such as the liver and
lung. The heart/liver uptake ratio was similar to other
rotenone-based MPI tracers 7′(Z)-125I-iodorotenol and
7′(Z)-125I-iodorotenone [12], as well as the benchmark
agent 99mTc-sestamibi [13]. Heart/stomach and heart/
intestine ratios remained moderate within the first 1 h
post-injection of the tracer, which allow for a good im-
aging window. At 24 h post-injection, a good clearance
of tracer on the whole-body scale was also observed.
Depending on the chemical nature, dehalogenation
in vivo of radioiodinated tracers occurs at different
paces, which eventually leads to the various degrees of
thyroid accumulation of radioactive iodine. We comparedthe thyroid uptake value of 123I-CMICE-013 to the data of
two closely related compounds 7′(Z)-125I-iodorotenol and
7′(Z)-125I-iodorotenone [12], which were acquired with
tissue biodistribution method (Figure 9). At 1 h, 123I-
CMICE-013 (0.483 ± 0.173 %ID/organ) activity was about
3 times that of 7′(Z)-125I-iodorotenol (0.139 ± 0.047 %ID/
organ) and 7′(Z)-125I-iodorotenone (0.154 ± 0.057 %ID/or-
gan); whereas at 24 h, 123I-CMICE-013 (0.693 ± 0.235
%ID/organ) was only one seventh of 7′(Z)-125I-iodorote-
nol (5.037 ± 0.341 %ID/organ) and one sixth of 7′(Z)-125I-
iodorotenone (3.784 ± 0.647 %ID/organ). Such difference
in thyroid uptake may indicate a slow and steady pace of
tracer degradation for 123I-CMICE-013, albeit the different
evaluation methods (imaging versus tissue) would have
also contributed to the discrepancy in the results between
the two studies.
We also compared the radiation dosimetry of 123I-
CMICE-013 to 7′(Z)-123I-iodorotenone, an 123I-labeled
rotenone derivative. Broaisat et al. performed a preliminary
radiation dose estimate on dogs injected with 7′(Z)-123I-
iodorotenone using MIRDOSE 3.1 [16]. Selected organs
were evaluated, including the gallbladder wall (3.08E-
01 mSv/MBq), stomach (1.24E-01 mSv/MBq), heart wall
(8.11E-03 mSv/MBq), kidneys (1.08E-02 mSv/MBq), liver
(1.08E-02 mSv/MBq), and salivary gland (1.78E-01 mSv/
MBq). Compared to the matched organs in our study,
the dose values of 123I-CMICE-013 injection were over-
all lower: stomach 1.36E-02 mSv/MBq for male; 1.64E-
02 mSv/MBq for female, kidneys 4.87E-03 mSv/MBq
for male and 6.08E-03 mSv/MBq for female, and liver
5.76E-03 mSv/MBq for male and 7.48E-03 mSv/MBq
for female. As for all radioiodine-based tracers, the
radiation dosimetry in the thyroid always attracts atten-
tion due to the potential for tracer de-iodination and
subsequent uptake in the thyroid. Our estimate suggested
that 123I-CMICE-013 created a mild dose to thyroid
(1.24E-02 mSv/MBq for male; 1.44E-02 mSv/MBq for
female), only about one-fifth of that of 7′(Z)-123I-iodorote-
none (7.03E-02 mSv/MBq). Nevertheless, as is frequently
done with 123I-compound in current clinical use, a thyroid-
blocking agent could be administered to further reduce
thyroid exposure.
Our radiodosimetry analysis also indicated that 123I-
CMICE-013 created a moderate whole-body effective
dose that is lower than both benchmark MPI tracers
99mTc-sestamibi (9.0E-03 mSv/MBq at rest) and 99mTc-
tetrofosmin (7.6E-03 mSv/MBq at rest) [5]. It is also well
within the range of ICRP 80 listed 123I-based tracers [5]
and highly competitive among other novel tracers that
are currently under investigation. 123I-MNI-420, a SPECT
tracer for imaging A2A receptor in brain, had an effective
dose of 3.60E-02 mSv/MBq [17]. The effective dose of
123I-βCIT (dopamine transporter imaging agent) and
123I-ADAM (serotonin transporter imaging agent) were
Figure 8 Time-activity curves of 123I-CMICE-013 in seven organs plus remainder. In order to best demonstrate the percentage of injected
dose per organ values of a large scale, the time-activity curves are split into two graphs, A and B. An exponential fitting curve is fitted for both
the liver and the heart. Results were expressed as mean ± SD (n = 6).
Table 4 Rat and human residence times






Bladder (contents) 7.26E-02 2.99E-02
Intestine (ULI) 2.35E-01 3.34E-02
Intestine (LLI) 1.44E-01 2.05E-02
Intestine (small) 2.32E-01 6.07E-02
Remainder 4.79 5.1
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http://www.ejnmmires.com/content/4/1/16estimated to be 3.10E-02 mSv/MBq [18] and 3.37E-
02 mSv/MBq [19]. A dosimetry analysis based on a canine
model injected with 7′(Z)-123I-iodorotenone revealed that
the tracer gave an effective dose of 2.97E-03 mSv/MBq
[16]. Given that the current estimate for123I-CMICE-013
was based on a limited number of healthy rats, data
should be interpreted as preliminary and future studies
in large animals, and eventually, human subjects are
critical for a more precise and accurate measure of
radiodosimetry.
This study describes the characterization of the biodis-
tribution profile of 123I-CMICE-013 using microSPECT
image-based quantification. For studying radiotracer
uptake in small animal models, the quantitative SPECT
imaging has several advantages over purely tissue-
sampling-based methods. As a non-invasive method, it
allows repeat three-dimensional imaging of the same
animal over multiple time points [20,21]. We acquired
six time points after a single injection of tracer for each










Adrenals 5.35E-03 2.68E-05 6.72E-03 3.36E-05
Brain 3.84E-03 1.92E-05 4.86E-03 2.43E-05
Breasts 3.40E-03 1.70E-04 4.36E-03 2.18E-04
LLI 6.63E-03 7.96E-04 7.96E-03 9.55E-04
SI 6.82E-03 3.41E-05 7.80E-03 3.90E-05
Stomach 1.36E-02 1.63E-03 1.64E-02 1.97E-03
ULI 6.92E-03 3.46E-05 8.44E-03 4.22E-05
Kidneys 4.87E-03 2.44E-05 6.08E-03 3.04E-05
Liver 5.76E-03 2.88E-04 7.48E-03 3.74E-04
Lungs 4.81E-03 5.77E-04 6.33E-03 7.60E-04
Muscle 4.17E-03 2.09E-05 5.16E-03 2.58E-05
Pancreas 6.49E-03 3.25E-05 8.03E-03 4.02E-05
Red marrow 3.91E-03 4.69E-04 4.73E-03 5.68E-04
Osteogenic cells 1.37E-02 1.37E-04 1.76E-02 1.76E-04
Skin 2.89E-03 2.89E-05 3.53E-03 3.53E-05
Spleen 5.29E-03 2.65E-05 6.58E-03 3.29E-05
Testes (m)/Ovary (f) 3.92E-03 7.84E-04 6.77E-03 1.35E-03
Thymus 4.92E-03 2.46E-05 6.19E-03 3.10E-05
Thyroid 1.24E-02 6.20E-04 1.44E-02 7.20E-04
Bladder 6.56E-03 3.28E-04 8.28E-03 4.14E-04
Uterus 5.58E-03 2.79E-05 6.63E-03 3.32E-05
ED ICRP 60 6.99E-03
ED ICRP 103 7.15E-03
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http://www.ejnmmires.com/content/4/1/16animal. This reduces the amount of tracer product that
needs to be formulated for evaluation, decreases the
number of animals needed to obtain the data points,
and improves the consistency in the time-activity curves
by removing any subject-to-subject variability. The imagesTable 6 Effective doses of 123I-based tracers listed in
ICRP 80 [5]
Tracer EDE (mSv/MBq)
Iodide (thyroid blocked, uptake 0%) 1.10E-02
Iodide (thyroid uptake 35%) 2.20E-01
Iodoamphetamine (IMP) 2.70E-02
Iodine-labeled fibrinogen 2.00E-02
Iodine-labeled albumin (HSA) 2.00E-02
Iodine-labeled microaggregated albumin (MIAA) 1.80E-02
Hippuran 1.20E-02
Hippuran, bladder emptied 1 h after administration 4.60E-03
Hippuran, bladder emptied 0.5 h after administration 5.90E-03
Metaiodobenzylguanidine (MIBG) 1.30E-02
Sodium rose bengal 5.90E-02provide a full in vivo picture of the entire animal at each
time point, which removes any distortion of distribution
or losses of tracer that may be caused by sacrificing the
animal and tissue sectioning. Finally the image ensures
that samples can be taken from all relevant sites of focal
uptake, reducing the possibility of not acquiring samples
from sites of unexpected tracer accumulation. For instance,
the salivary glands were not collected during tissue extrac-
tion in this study because it was not realized a priori that
123I-CMICE-013 would accumulate in these tissues.
The data from image analysis is largely consistent with
those from tissue sampling. For most organs, the %ID/
organ values showed no significant difference between
the data from two methods. The correlation analysis also
showed an excellent correlation (r = 0.882) overall. The
one exception was the uptake in the intestine. A limitation
of the quantitative SPECT imaging approach is a reduced
sensitivity [22]. As the organs are evaluated in situ, the
presence of uptake in surrounding or nearby tissues gener-
ates a background that reduces sensitivity compared to
that obtained when the tissue is removed from the subject.
We suspect that the differences seen in the intestine were
Figure 9 Thyroid uptake of 123I-CMICE-013 versus two other
perfusion agents. The thyroid uptake values (%ID/organ) of two
7'(Z)-125I-iodorotenol and 7′(Z)-125I-iodorotenone were compared to
123I-CMICE-013 at 1, 2, and 24 h post-injection. A 102-min data of 123I-
CMICE-013 was used as 2-h data in this graph. All data were expressed
as mean ± SD. The number of animals at each time point (in the order
of 1, 2, 24 h) is 123I-CMICE-013 n = 6, 6, 8; 7'(Z)-125I-iodorotenol n = 3, 4,
4; 7'(Z)-125I-iodorotenone n = 7, 6, 4. * P < 0.05, ** P < 0.001,
*** P < 0.0001 versus 123I-CMICE-013 at the same time point.
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http://www.ejnmmires.com/content/4/1/16due to diffuse uptake in the intestinal walls that was
not resolved over background in the images and thus
not included in the organ activity estimate. An additional
contributing factor could be the limited resolution of the
camera [22]. Partial volume effects will dilute the apparent
uptake in small structures and could make small organs
with low levels of uptake difficult to distinguish from
background [23]. A final limitation is the difficulty of iden-
tifying anatomical structures and boundaries of structures
from the tracer distribution image. We mitigated this
using a co-registered CT scan for anatomical localization,
which has been proven to greatly improve the ease of
identification of anatomical regions [24-26]. Due to the
fact that CT still suffers from poor soft-tissue contrast,
ultimately the use of a co-registered MRI might prove
more beneficial. Without a definite measure of tissue
boundaries, estimates of organ mass are also reduced in
accuracy and this increases the uncertainty of converting
data into measures of %ID/g of tissue. Thus, in lieu of a
purely image-based or tissue sample-based approach, a
hybrid method such as that used in this study may provide
the advantages of both. Using multiple image points
and tissue sampling coincident with the final time pro-
vides the opportunity to specifically target sampling of
small organs and also provides accurate measures of
organ volumes and weights. The good consistency and
correlation between the data from the two methods
suggested that our hybrid imaging-based quantificationtechnique is a powerful tool to monitor the kinetics
distribution of SPECT radiotracers.
Conclusions
This study represents an exploratory investigation of the
123I-CMICE-013 biodistribution profile using in vivo
whole-body imaging and validation with tissue analysis.
Our tracer under development demonstrated biodistri-
bution features of a desirable myocardial perfusion im-
aging agent, such as the high myocardium uptake, rapid
liver clearance, and lack of lung activity. Furthermore,
results from radiodosimetric analysis suggest low organ
doses and a modest whole-body dose, which provides a
favorable justification for prospective dosimetry studies
in larger animals and humans.
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